Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of 90Y-Labeled IDEC-159 in Metastatic Colorectal Cancer
NCT00102024Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jan 2005
- Primary completion
- Jan 2006
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of IDEC-159 in colorectal cancer (CRC), sponsored by Biogen. Started Jan 2005; status: terminated.
02
Drugs
IDEC-159
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00102024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102024.